1. Introduction
===============

It is well known that many of heterocyclic compounds containing oxygen display important biological properties such as antiarrhytmic, spasmolitic, antiviral, anticancer, antifungal and anti-inflammatory activity \[[@B1-molecules-15-04737],[@B2-molecules-15-04737],[@B3-molecules-15-04737],[@B4-molecules-15-04737],[@B5-molecules-15-04737],[@B6-molecules-15-04737],[@B7-molecules-15-04737]\]. This group of compounds includes the furobenzopyranone, benzofuran, and benzopyranone systems. Good examples of the above mentioned are the drugs amiodarone, benziodarone and benzbromarone ([Figure 1](#molecules-15-04737-f001){ref-type="fig"}).

![The structures of amiodarone, benzbromarone and benzidarone.](molecules-15-04737-g001){#molecules-15-04737-f001}

Amiodarone is used clinically as an antiarrhytmic agent causing alternations in calcium homeostasis, and cell death in yeasts and it also possesses antifungal activity \[[@B1-molecules-15-04737],[@B8-molecules-15-04737],[@B9-molecules-15-04737],[@B10-molecules-15-04737],[@B11-molecules-15-04737]\]. Benziodarone is a vasodilator \[[@B12-molecules-15-04737]\], and benzbromarone is effective in lowering uric acid levels, as well as reducing the number of acute gout attacks in patients for whom other treatments are ineffective \[[@B13-molecules-15-04737],[@B14-molecules-15-04737]\]. Although the last two compounds were withdrawn from the market because of their serious side effects, amiodarone is still used. Due to the interesting biological activity of these compounds, it seemed worthwhile to search for new compounds with similar structures in order to identify potentially less toxic compounds, much safer for health and the environment. Other examples of compounds with related structures showing biological activity ([Figure 2](#molecules-15-04737-f002){ref-type="fig"}) can be found in the literature. Compound **1**, for example, shows high affinity for adrenergic receptors and possesses antidepressive activity \[[@B16-molecules-15-04737]\]. Derivative **2** inhibits absorption of biogenic amines \[[@B15-molecules-15-04737]\] and **3** decreases blood pressure \[[@B17-molecules-15-04737]\].

![The structures of halo derivatives of benzofurans: methyl 5-chloro-1-benzofuran-2-carboxylate (**1**); 5-bromo-3-hydroxy-1-benzofuran-2-yl)(4-methoxyphenyl)methanone (**2**); 6,7-dichloro-5-\[(*Z*)-\[methoxy(oxido)-λ^5^-azanylidene\](methyl)-λ^4^-sulfanyl\]-1-benzo-furan-2-carboxylic acid (**3**).](molecules-15-04737-g002){#molecules-15-04737-f002}

For many years we have been involved in research in the field of synthesis of new biologically active benzofurans. A large number of compounds synthesized by our team contain halogens in their structure and some of them have shown biological activity \[[@B19-molecules-15-04737],[@B20-molecules-15-04737],[@B21-molecules-15-04737]\], e.g. compounds **4**and **5**([Figure 3](#molecules-15-04737-f003){ref-type="fig"}).

![The structures of methyl 5-bromo-7-hydroxy-6-methoxy-1-benzofuran-2-carboxylate (**4**); methyl 5-bromo-7-\[2-(diethylamino)ethoxy\]-6-methoxy-1-benzofuran-2-carboxylate (**5**).](molecules-15-04737-g003){#molecules-15-04737-f003}

These two compounds showed significant cytotoxic activity against human cancer cell lines. Additionally, derivative **5** demonstrated antifungal activity. Some 1-(3-amino-2-hydroxypropyl) derivatives of 4,5,6-tribromo-2,3-dihydro-2,2-dimethyl-7-benzofuranol ([Figure 4](#molecules-15-04737-f004){ref-type="fig"}) are effective against Gram-positive bacteria and fungi \[[@B20-molecules-15-04737],[@B21-molecules-15-04737]\]. Our research shows that brominated compounds display lower cytotoxity than the corresponding precursor compounds before bromination. \[[@B20-molecules-15-04737],[@B21-molecules-15-04737]\].

![The general structure **6** of 1-(3-amino-2-hydroxypropyl) derivatives of 4,5,6-tribromo-2,3-dihydro-2,2-dimethyl-7-benzofuranol.](molecules-15-04737-g004){#molecules-15-04737-f004}

Compound **7** ([Figure 5](#molecules-15-04737-f005){ref-type="fig"}) and its analogues are the topic of a patent application \[[@B22-molecules-15-04737]\]. Compounds of this invention exhibit synergistic antifungal activity in combination with the antifungal compound amiodarone. They are further useful as antifungal agents for the prevention and/or treatment of fungal infections in plants.

![The structure of methyl 7-acetyl-5-bromo-3-(bromomethyl)-6-hydroxy-1-benzofuran-2-carboxylate (**7**).](molecules-15-04737-g005){#molecules-15-04737-f005}

In light of this information we have decided to continue our research, and thus design and synthesize some new compounds that might show antimicrobial activity ([Scheme 1](#molecules-15-04737-f008){ref-type="scheme"}).

2. Results and Discussion
=========================

2.1. Chemistry
--------------

The chosen starting material was 6-acetyl-5-hydroxy-2-methyl-1-benzofuran-3-carboxylic acid. Compounds **I** \[[@B18-molecules-15-04737],[@B19-molecules-15-04737]\] and **II** were obtained by mono- or dimethylation of the starting material with dimethyl sulphate, respectively. Next, the corresponding bromo and/or chloro derivatives were synthesized. As a result, the benzofuran ring of compound **I** was substituted on C4 and the acetyl group by halogen and we thus obtained methyl 4-bromo-6-(dibromoacetyl)-5-hydroxy-2-methyl-1-benzofuran-3-carboxylate (**III**), methyl 4-chloro-6-(chloroacetyl)-5-hydroxy-2-methyl-1-benzofuran-3-carboxylate (**V**) and methyl 4-chloro-6-(dichloroacetyl)-5-hydroxy-2-methyl-1-benzofuran-3-carboxylate (**VI**). In the case of compound **II**, only acetyl group halogenations were observed (**IV**, **VII**). ^1^H-NMR spectra were obtained for all of the synthesized structures, and for compound **VI** an X-ray crystal structure was obtained too.

![Method of preparation of compounds **I**--**VII**.](molecules-15-04737-g008){#molecules-15-04737-f008}

2.2. NMR spectra
----------------

Analysis of the ^1^H-NMR spectra for the obtained derivatives **III**, **V** and **VI** shows no acetyl group signals, whereas for 6-acetyl-5-hydroxy-2-methyl-3-benzofuranocarboxylic acid we observe a singlet signal for this group for with a chemical shift value of 2.78 ppm. On the other hand, we observed additional signals at 4.74 ppm for compound **V**, at 6.73 ppm for compound **VI**, and at 6.72 ppm for compound **III**, indicating that hydrogens in the acetyl group were substituted by chlorine or bromine. Additionally, for these compounds we do not observe any hydrogen signal for C4, which suggests that it was substituted by chlorine or bromine, too. We obtained similar ^1^H-NMR spectra for compounds **IV,** **VII**.

2.3. X-Ray structure analysis
-----------------------------

In order to confirm the structure of **VI**, the molecular and crystal structure in the solid state was analyzed by single crystal X-ray diffraction. Suitable crystals could only be obtained only for this derivative. A view of the molecular structure together with the atomic numbering scheme is shown in [Figure 6](#molecules-15-04737-f006){ref-type="fig"} (the drawings were performed with the Mercury program \[[@B23-molecules-15-04737]\]).

![A view of the molecule of **VI**.](molecules-15-04737-g006){#molecules-15-04737-f006}

The results indicate that compound **VI** crystallizes in the monoclinic space group P 2~1~/c with one ordered molecule in the asymmetric unit. Selected bond lengths, bond angles and torsion angles are listed in [Table 1](#molecules-15-04737-t001){ref-type="table"}.

molecules-15-04737-t001_Table 1

###### 

Selected bond lengths \[Å\] and angles \[deg\] and selected torsional angles \[deg\] for **VI**.

  ---------------- -----------
  O1-C2            1.354(2)
  O1-C8            1.371(2)
  C5-O15           1.346(2)
  C5-C6            1.429(3)
  C6-C16           1.463(3)
  C2-O1-C8         107.1(1)
  C3-C11-O13       110.4(2)
  C6-C16-O17       123.3(2)
  C9-C3-C2-C10     -178.5(2)
  C3-C9-C4-Cl1     -0.1(3)
  C7-C6-C5-O15     -177.3(2)
  C6-C16-C18-Cl2   81.9(2)
  C6-C16-C18-Cl3   -157.7(2)
  ---------------- -----------

The geometry of the benzofuran ring is comparable to that found in other benzofuran derivatives \[[@B19-molecules-15-04737],[@B24-molecules-15-04737],[@B25-molecules-15-04737],[@B26-molecules-15-04737]\]. Only the C5-C6 bond length in the benzene seems rather longer due to the substituent at C6 indicating a π-electron delocalization within this fragment of the molecule. The benzofuran moiety is essentially planar with a maximum deviation of 0.017(2)Å for C6. The methoxycarbonyl group is planar to within 0.007Å and makes an angle of 18.65(6)^o^ with plane of the benzofuran system. The C10, O15, Cl1 atoms are almost coplanar with the benzofuran fragment (the appropriate torsion angles are given in [Table 1](#molecules-15-04737-t001){ref-type="table"}) and the C16, O17 and C18 atoms are found to be only marginally out of the plane of the two-ring framework \[max. deviation of 0.172(3)Å for O17\]. Only halogen atoms, Cl2 and Cl3, are considerably out of the mentioned plane (see [Table 1](#molecules-15-04737-t001){ref-type="table"}). Strong intramolecular hydrogen bonding is present between O15 and O17 atoms (see [Figure 6](#molecules-15-04737-f006){ref-type="fig"} and [Table 2](#molecules-15-04737-t002){ref-type="table"}). The angle between the best planes of the benzofuran and the C5/O15/H15/O17/C16/C6 moiety is only 4.37(4)^o^. Additionally the C11=O12···Cl1-C4 halogen bond \[3.018(2)Å\] stabilizes the conformation of the molecule.

In the crystal of **VI**, the packing of the molecules is determined by intermolecular C-H···O hydrogen bonds, Cl···O, C···O interactions and stacking forces. The molecules are linked by C14-H14A···O17 hydrogen bonds forming chains along the *a* axis, then adjacent chains are connect *via* C10-H10A···O15 and O1···Cl1 interactions to form layers parallel to the (001) plane ([Figure 7](#molecules-15-04737-f007){ref-type="fig"}).

![The interconnections within a layer for **VI**.](molecules-15-04737-g007){#molecules-15-04737-f007}

Cohesion between sheets results in Cl···O, C···O interactions and stacking forces. The geometric parameters of all intra- and intermolecular interactions are given in [Table 2](#molecules-15-04737-t002){ref-type="table"}.

molecules-15-04737-t002_Table 2

###### 

Intra- and intermolecular interactions in crystals of **VI**(Å, deg).

  -------------------- ------ ------- ---------- --------------
  D-H···A              D-H    H···A   D···A      \<( D-H···A)
  O15-H15···O17        0.82   1.86    2.580(2)   146
  C10-H10A···O15^i^    0.96   2.82    3.758(3)   165
  C14-H14A···O17^ii^   0.96   2.66    3.470(3)   142
  O12···Cl1                           3.018(2)   
  O1···Cl1^i^                         2.995(1)   
  C2···O12^iii^                       3.122(3)   
  Cl3···O15^iii^                      3.457(2)   
  C16···O15^iii^                      3.238(3)   
  -------------------- ------ ------- ---------- --------------

Symmetry codes: (i) -x+1, y+1/2, -z+1/2; (ii) x+1, y, z; (iii) x, -y+1/2, z+1/2.

2.4. Antimicrobial activity
---------------------------

All the synthesized 6-acetyl-5-hydroxy-2-methyl-3-benzofuranocarboxylic acid derivatives were tested for antimicrobial activity. The microorganisms used in this study included Gram-positive cocci, Gram-negative rods and yeasts. Compounds **III**, **IV**, **VI** were active against Gram-positive cocci: *Staphylococcus aureus* NCTC 4163, *Staphylococcus aureus* ATCC 25923, *Staphylococcus aureus* ATCC 6538, *Staphylococcus aureus* ATCC 29213, *Staphylococcus epidermidis* ATCC 12228, *Bacillus subtilis* ATCC 6633, *Bacillus cereus* ATCC 11778, *Micrococcus luteus* ATCC 9341, *Micrococcus luteus* ATCC 10240. Compounds **III**, **VI**showed antifungal activity against *Candida albicans* ATCC 10231, *Candida albicans* ATCC 90028 and *Candida parapsilosis* ATCC 22019. The results are summarized in [Table 3](#molecules-15-04737-t003){ref-type="table"}.

molecules-15-04737-t003_Table 3

###### 

Antimicrobial activity of derivatives **III**, **IV**, **VI**: diameter of the growth inhibition zone.

                                  Growth inhibition zones in mm (MIC values)                                        
  ------------------------------- -------------------------------------------- ---------- ---------- -------------- --------
  *S. aureus* NCTC 4163           12 (200)                                     12 (50)    12 (100)   26 (0.5)       nt
  *S. aureus* ATCC 25923          12 (200)                                     13 (50)    12 (200)   26 (0.5)       nt
  *S. aureus* ATCC 6538           12 (200)                                     14 (50)    12 (100)   28 (0.5)       nt
  *S. aureus* ATCC 29213          12 (200)                                     13 (50)    12 (100)   22 (0.5)       nt
  *S. epidermidis* ATCC 12228     12 (100)                                     14 (50)    13 (100)   30 (0.5)       nt
  *B. subtilis* ATCC 6633         12 (100)                                     13 (50)    13 (100)   40 (\<0.125)   nt
  *B. cereus* ATCC 11778          12 (100)                                     15 (50)    12 (100)   20 (1)         nt
  *E. hirae* ATCC 10541           \- (\> 400)                                  \- (200)   \- (400)   \- (4)         nt
  *M. luteus* ATCC 9341           12 (400)                                     15 (100)   12 (200)   22 (2)         nt
  *M. luteus* ATCC 10240          12 (100)                                     15 (50)    12 (100)   24 (1)         nt
  *E. coli* ATCC 10538            na                                           na         na         34 (\<0.125)   nt
  *E. coli* ATCC 25922            na                                           na         na         35 (\<0.125)   nt
  *E. coli* NCTC 8196             na                                           na         na         35 (\<0.125)   nt
  *P. vulgaris* NCTC 4635         na                                           na         na         36 (\<0.125)   nt
  *P. aeruginosa* ATCC 15442      na                                           na         na         25 (0.5)       nt
  *P. aeruginosa* NCTC 6749       na                                           na         na         26 (0.5)       nt
  *P. aeruginosa* ATCC 27853      na                                           na         na         23 (1)         nt
  *B. bronchiseptica* ATCC 4617   na                                           na         na         31 (1)         nt
  *C. albicans* ATCC 10231        12 (100)                                     na         13 (100)   nt             22 (1)
  *C. albicans* ATCC 90028        12 (100)                                     na         12 (100)   nt             32 (1)
  *C. parapsilosis* ATCC 22019    13 (100)                                     na         14 (100)   nt             22 (2)

na - no activity in disc diffusion test; - denotes lack of a growth inhibition zone; nt -- not tested.

Unsubstituted esters **I**, **II** showed no microbiological activity. The change of microbiological activity appears when a halogen is introduced into a benzofuran structure. Derivatives in which an acetyl group hydrogen was substituted by one halogen (**V**, **VII**) were inactive, in contrast to derivatives in which two acetyl group hydrogens were substituted by halogens (**III**, **IV**, **VI**). These compounds were active against Gram-positive cocci. Additionally, derivatives containing a halogen in the aromatic ring (**III**, **VI**) showed antifungal activity ([Table 3](#molecules-15-04737-t003){ref-type="table"}).

3. Experimental
===============

3.1. General
------------

Melting points were determined in a capillary in Electrothermal 9100 apparatus and are uncorrected. The proton nuclear magnetic resonance spectra (^1^H-NMR) were recorded in CDCl~3~ on a Varian UNITY-plus 300 spectrometer operating at 300 MHz. Chemical shift values are expressed in ppm (parts per million) in relation to tetramethylsilane as an internal standard. Mass spectral ESI (Electrospray Ionization) measurements were carried out on a Mariner PE Biosystems instrument with TOF detector. The spectra were obtained in the positive ion mode with a declustering potential 140--300 V. Elemental analyses were recorded with CHN model 2400 Perkin-Elmer. Chromatographic columns were filled with Merck Kieselgel 0.05--0.2 mm reinst (70--325 mesh ASTM) silica gel. Reactions were monitored by TLC on silica gel (plates with fluorescent indicator 254 nm, layer thickness 0.2 mm, Kieselgel G., Merck), using chloroform-methanol 98:2 and 95:5 as eluents.

*Methyl 6-acetyl-5-hydroxy-2-methyl-1-benzofuran-3-carboxylate* (**I**). A mixture of 6-acetyl-5-hydroxy-2-methyl-1-benzofuran-3-carboxylic acid (0.02 mole), K~2~CO~3~ (0.02 mole) and (CH~3~O)~2~SO~2~(0.02 mole) in acetone (30 mL) was refluxed for 5 h. When the reaction was complete, the mixture was filtered and the solvent was evaporated. The residue was purified by column chromatography on silica gel, eluent: chloroform. Yield: 87%; m.p. 170--171 °C; ^1^H-NMR δ (ppm): 12.17 (s, 1H, OH), 7.76 (s, 1H, C7-H), 7.46 (s, 1H, C4-H), 3.93 (s, 3H, COOCH~3~), 2.78 (s, 3H, COCH~3~), 2.67 (s, 3H, CH~3~); Anal. Calc. for C~13~H~12~O~5~: 62.90% C; 4.87% H; found: 62.87% C, 4.87% H; ESI MS m/z: 247.1, 248.8 (100%).

*Methyl 6-acetyl-5-methoxy-2-methyl-1-benzofuran-3-carboxylate* (**II**). A mixture of 6-acetyl-5-hydroxy-2-methyl-1-benzofuran-3-carboxylic acid (0.02 mole), K~2~CO~3~ (0.02 mole) and excess (CH~3~O)~2~SO~2~(0.06 mole) in acetone (30 mL) was refluxed for 10 h. When the reaction was complete, the boiling mixture was filtered and the solvent was evaporated. The residue was purified by column chromatography on silica gel, eluent: chloroform. Yield: 78%; m.p. 118--119 °C;^1^H-NMR δ (ppm): 7.83 (s, 1H, C7-H), 7.48 (s, 1H, C4-H), 3.87 (s, 3H, COOCH~3~), 3.95 (s, 3H, OCH~3~), 2.76 (s, 3H, COCH~3~), 2.65 (s, 3H, CH~3~); Anal*.* Calc. for C~14~H~14~O~5~: 64.12% C; 5.38% H; found 64.19% C; 5.39% H.

3.2 General procedure for synthesis of bromo derivatives of esters ***I*** and ***II***
---------------------------------------------------------------------------------------

The appropriate ester **I** or **II** (0.02 mole) was dissolved in CHCl~3~ (20 mL) then a solution of bromine (0.04 mole) in CHCl~3~ (10 mL) was added dropwise with stirring for 0.5 h. Stirring was continued for 8 h at room temperature. When the reaction was complete the solvent was evaporated. The residue was purified by column chromatography on silica gel, eluent: chloroform.

*Methyl 4-bromo-6-(dibromoacetyl)-5-hydroxy-2-methyl-1-benzofuran-3-carboxylate* (**III**). Yield: 77%; m.p. 149--150 °C; ^1^H-NMR δ (ppm): 11.98(s, 1H, OH), 8.00 (s, 1H, C7-H), 6.72 (s, 1H, COCHBr~2~), 3.95 (s, 3H, COOCH~3~), 2.63 (s, 3H, CH~3~); Anal. Calc. for C~13~H~9~O~5~Br~3~: 32.20% C; 1.87% H; found 32.38% C; 2.09% H; ESI MS m/z: 506.8:508.7 \[M+Na\]^+^ (100%).

*Methyl 6-(dibromoacetyl)-5-methoxy-2-methyl-1-benzofuran-3-carboxylate* (**IV**). Yield: 78%; m.p. 135--138 °C; ^1^H-NMR δ (ppm): 7.95 (s, 1H, C7-H), 7.54 (s, 1H, C4-H), 7.22 (s, 1H, COCHBr~2~), 4.05 (s, 3H, COOCH~3~), 3.98 (s, 3H, OCH~3~), 2.80 (s, 3H, CH~3~); Anal*.* Calc. for C~14~H~12~O~5~Br~2~: 40.03% C; 2.88% H; found 39.94% C; 2.77% H.

3.3. General procedure for synthesis of chloro derivatives of esters ***I*** and ***II***
-----------------------------------------------------------------------------------------

The appropriate ester **I** or **II** (0.02 mole) was dissolved in CHCl~3~ (20 mL). Next chlorine~,~ obtained in the reaction of KMnO~4~ with concentrated HCl, was passed through the solution. When the reaction was complete the solvent was evaporated. The residue was purified by column chromatography on silica gel, eluents: chloroform and chloroform/methanol 100:0.5.

*Methyl 4-chloro-6-(chloroacetyl)-5-hydroxy-2-methyl-1-benzofuran-3-carboxylate* (**V**). Yield: 23%; m.p. 187--188 °C; ^1^H-NMR δ (ppm): 12.11 (s, 1H, OH), 7.74 (s, 1H, C7-H), 4.74 (s, 2H, COCH~2~Cl), 3.96 (s, 3H, COOCH~3~), 2.68 (s, 3H, CH~3~);; Anal. Calc. for C~13~H~10~O~5~Cl~2~: 49.24% C; 3.18% H; found 49.14% C; 3.24% H; ESI MS m/z: 339.6:341\[M+Na\]^+^ (100%).

*Methyl 4-chloro-6-(dichloroacetyl)-5-hydroxy-2-methyl-1-benzofuran-3-carboxylate* (**VI**). Yield: 36%; m.p. 171--172 °C;^1^H-NMR δ (ppm): 11.70 (s, 1H, OH), 7.98 (s, 1H, C7-H), 6.73 (s, 1H, COCHCl~2~), 3.96 (s, 3H, COOCH~3~), 2.68 (s, 3H, CH~3~); Anal. Calc. for C~13~H~9~O~5~Cl~3~: 44.41% C; 2.58% H; found 44.60% C; 2.71% H; ESI MS m/z: 350.8:352.6 \[M+H\]^+^ (100%).

*Methyl 6-(chloroacetyl)-5-methoxy-2-methyl-1-benzofuran-3-carboxylate* (**VII**). Yield: 54%; m.p. 130--131 °C; ^1^H-NMR δ (ppm): 7.69 (s, 1H, C7-H), 7.19 (s, 1H, C4-H), 4.75 (s, 2H, COCH~2~Cl), 3.88 (m, 6H, COOCH~3~, OCH~3~), 2.60 (s, 3H, CH~3~); Anal. Calc. for C~14~H~13~O~5~Cl\*2H~2~O: 50.53% C; 3.90% H; found 50.60% C; 3.90% H.

3.4. Crystallography
--------------------

Crystals of **VI** suitable for X-ray analysis were grown from acetic acid solution by slow evaporation. All details of the measurements, crystal data and structure refinement are given in [Table 4](#molecules-15-04737-t004){ref-type="table"}. The data were collected on an Oxford Diffraction KM4CCD diffractometer \[[@B27-molecules-15-04737]\] at 293 K, using graphite-monochromated *MoK~α~* radiation. The unit cell parameters were determined by least-squares treatment of setting angles of highest-intensity reflections chosen from the whole experiment. Intensity data were corrected for the Lorentz and polarization effects \[[@B28-molecules-15-04737]\]. The structure was solved by direct methods by use the SHELXS97 program \[[@B29-molecules-15-04737]\] and refined by the full-matrix least-squares method with the SHELXL97 program \[[@B30-molecules-15-04737]\]. Two reflections were excluded from the reflection file due to their large (\|F~o~\|^2^-\|F~c~\|^2^) differences. The function Σw(\|F~o~\|^2^-\|F~c~\|^2^)^2^ was minimized with w^‑1^= \[σ^2^(F~o~)^2^+(0.0474P)^2^+0.6944P\], where P = (F~o~^2^+2F~c~^2^)/3. All non-hydrogen atoms were refined with anisotropic thermal parameters. The coordinates of the hydrogen atoms were calculated in idealized positions and refined as a riding model with their thermal parameters calculated as 1.2 (1.5 for methyl group) times U~eq~ of the respective carrier carbon atom. An empirical extinction correction was also applied according to the formula F~c~' = kF~c~\[1+(0.001χF~c~^2^λ^3^/sin2θ)\]^-1/4^ \[[@B30-molecules-15-04737]\], and the extinction coefficient χ was equal to 0.008(1). The deposition number CCDC 700768 contains the supplementary crystallographic data of compound **VI** for this paper. These data can be obtained free of charge via [www.ccdc.cam.ac.uk/data_request/cif](www.ccdc.cam.ac.uk/data_request/cif), or by emailing data_request\@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

molecules-15-04737-t004_Table 4

###### 

Crystal data, data collection and structure refinement for compound **VI**.

  ------------------------------------- ------------------------
  Compound                              **VI**
  Empirical formula                     C~13~H~9~O~5~Cl~3~
  Formula weight                        351.55
  *T* (K)                               293(2)
  Wavelength (Å)                        0.71073
  Crystal system, space group           monoclinic, *P* 2~1~/c
  Unit cell dimensions                  
  *a* (Å)                               13.0544(3)
  *b* (Å)                               15.7053(3)
  *c* (Å)                               7.0108(2)
  *β* (^o^)                             104.897(3)
  Volume (Å^3^)                         1389.07(6)
  *Z*, *D~x~*(Mg/m^3^)                  4, 1.681
  *μ* (mm^-1^)                          0.677
  *F*(000)                              712
  *θ* range for data collection (^o^)   2.07 -- 25.00
  *hkl* range                           -15 ≤ h ( 15
                                        -18 ( k ( 18
                                        -8 ( l ( 8
  Reflections:                          
  collected                             13369
  unique (Rint)                         2409(0.019)
  observed (I \> 2((I))                 2003
  Data / restraints / parameters        2409 / 0 / 191
  Absorption correction                 multi-scan
  Goodness-of-fit on *F^2^*             1.055
  *R*(*F*) (*I* \> 2*σ*(*I*))           0.0293
  *wR*(*F^2^*) (all data)               0.0895
  Max/min. Δ*ρ* (e/ Å^3^)               0.315 / -0.237
  ------------------------------------- ------------------------

3.5. Microbiology
-----------------

The antimicrobial activity of compounds was tested against a series of microorganisms obtained from the collection of the Department of Pharmaceutical Microbiology, Medical University of Warsaw (Poland), including: Gram-positive cocci: *Staphylococcus aureus* NCTC 4163, *Staphylococcus aureus* ATCC 25923, *Staphylococcus aureus* ATCC 6538, *Staphylococcus aureus* ATCC 29213, *Staphylococcus epidermidis* ATCC 12228, *Bacillus subtilis* ATCC 6633, *Bacillus cereus* ATCC 11778, *Enterococcus hirae* ATCC 10541, *Micrococcus luteus* ATCC 9341, *Micrococcus luteus* ATCC 10240; Gram-negative rods: *Escherichia coli* ATCC 10538, *Escherichia coli* ATCC 25922*,Escherichia coli* NCTC 8196, *Proteus vulgaris* NCTC 4635, *Pseudomonas aeruginosa* ATCC 15442, *Pseudomonas aeruginosa* NCTC 6749, *Pseudomonas aeruginosa* ATCC 27863, *Bordetella bronchiseptica* ATCC 4617 and yeasts: *Candida albicans* ATCC 10231, *Candida albicans* ATCC 90028, *Candida parapsilosis* ATCC 22019.

Antimicrobial activity was examined by the disc-diffusion method and the MIC method under standard conditions using Mueller-Hinton II agar medium (Becton Dickinson) for bacteria or RPMI agar medium (Sigma) with 2% glucose for fungi, according to CLSI guidelines \[[@B31-molecules-15-04737],[@B32-molecules-15-04737]\]. For the disc diffusion assay sterile filter paper discs (9 mm diameter, Whatman No 3 chromatography paper) were wetted with tested compound solutions (in DMSO) to load 400 μg of a given compound per disc. For MIC determinations concentrations of tested compounds in solid medium ranged from 6.25 to 400 μg/mL. The final inoculum, of all microorganisms were 10^4^ CFU mL^-1^ (colony forming units per mL), except the final inoculum for *E. hirae* ATCC 10541, which was 10^5^ CFU mL^-1^. The results were read after 18 h (for bacteria) or 24 h (for fungi) of incubation at 35 °C. The results are summarized in [Table 3](#molecules-15-04737-t003){ref-type="table"}.

4. Conclusions
==============

This study describes the synthesis and preliminary microbiological investigations of some 3-benzofurancarboxylic acid derivatives. Seven derivatives were examined. It was noticed that compounds not possessing halogen in their structure did not show any activity during the experiments, whereas compounds possessing halogens in their structure showed such activity. Halogens were introduced to alkyl substituent as well as to the aromatic ring. Derivatives in which the halogen, without the regard for the kind, was introduced in the aromatic ring, showed better activity, as these compounds displayed both antimicrobial and antifungal activity. Basing on these findings, as well as on results from our earlier investigations, we can confirm that the search for biologically active compounds in the area of halogen derivatives of benzofurans remains an interesting field from the biological point of view.

*Sample Availability:* Samples of the compounds are available from the authors.
